OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research report on Wednesday, November 13th.

OncoCyte Stock Down 1.4 %

Shares of OncoCyte stock opened at $2.13 on Thursday. The company has a fifty day moving average of $2.66 and a 200 day moving average of $2.91. OncoCyte has a fifty-two week low of $1.98 and a fifty-two week high of $3.82.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The company had revenue of $0.12 million during the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same quarter in the prior year, the firm posted ($0.57) EPS. On average, analysts anticipate that OncoCyte will post -2.57 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Andrea S. James purchased 20,000 shares of the business’s stock in a transaction dated Thursday, December 5th. The shares were purchased at an average price of $2.29 per share, for a total transaction of $45,800.00. Following the completion of the purchase, the chief financial officer now owns 53,670 shares in the company, valued at approximately $122,904.30. This represents a 59.40 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Andrew Arno acquired 12,500 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was acquired at an average cost of $2.11 per share, with a total value of $26,375.00. Following the completion of the purchase, the director now owns 81,554 shares of the company’s stock, valued at $172,078.94. This trade represents a 18.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 1,381,509 shares of company stock valued at $4,052,425. Company insiders own 1.58% of the company’s stock.

Institutional Investors Weigh In On OncoCyte

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC boosted its holdings in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the period. Geode Capital Management LLC owned approximately 0.62% of OncoCyte worth $296,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.